
PMC:7461420 / 14934-15174
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T85","span":{"begin":199,"end":206},"obj":"Body_part"}],"attributes":[{"id":"A85","pred":"fma_id","subj":"T85","obj":"http://purl.org/sig/ont/fma/fma82753"}],"text":"d on this, they designed peptides P4 (IC50, 50 µM) and P5 (IC50, 6.0 µM) with significant inhibitory activity against SARS‐CoV‐1. The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (re"}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T88","span":{"begin":118,"end":122},"obj":"Disease"}],"attributes":[{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"d on this, they designed peptides P4 (IC50, 50 µM) and P5 (IC50, 6.0 µM) with significant inhibitory activity against SARS‐CoV‐1. The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (re"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T152","span":{"begin":25,"end":33},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T153","span":{"begin":34,"end":36},"obj":"http://purl.obolibrary.org/obo/CLO_0008337"},{"id":"T154","span":{"begin":101,"end":109},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T155","span":{"begin":144,"end":152},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T156","span":{"begin":226,"end":233},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T157","span":{"begin":234,"end":236},"obj":"http://purl.obolibrary.org/obo/CLO_0008337"}],"text":"d on this, they designed peptides P4 (IC50, 50 µM) and P5 (IC50, 6.0 µM) with significant inhibitory activity against SARS‐CoV‐1. The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (re"}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T94","span":{"begin":25,"end":33},"obj":"Chemical"},{"id":"T95","span":{"begin":34,"end":36},"obj":"Chemical"},{"id":"T96","span":{"begin":134,"end":143},"obj":"Chemical"},{"id":"T97","span":{"begin":199,"end":206},"obj":"Chemical"},{"id":"T100","span":{"begin":226,"end":233},"obj":"Chemical"},{"id":"T101","span":{"begin":234,"end":236},"obj":"Chemical"}],"attributes":[{"id":"A94","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A95","pred":"chebi_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/CHEBI_35895"},{"id":"A96","pred":"chebi_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A97","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_15428"},{"id":"A98","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_29947"},{"id":"A99","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_57305"},{"id":"A100","pred":"chebi_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A101","pred":"chebi_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/CHEBI_35895"}],"text":"d on this, they designed peptides P4 (IC50, 50 µM) and P5 (IC50, 6.0 µM) with significant inhibitory activity against SARS‐CoV‐1. The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (re"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"504","span":{"begin":118,"end":126},"obj":"Species"},{"id":"509","span":{"begin":199,"end":206},"obj":"Chemical"}],"attributes":[{"id":"A504","pred":"tao:has_database_id","subj":"504","obj":"Tax:694009"},{"id":"A509","pred":"tao:has_database_id","subj":"509","obj":"MESH:D005998"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"d on this, they designed peptides P4 (IC50, 50 µM) and P5 (IC50, 6.0 µM) with significant inhibitory activity against SARS‐CoV‐1. The antiviral activity was further improved when they introduced the glycine binding linkage of peptide P4 (re"}